PeptiDream unit and Curium join forces on radiopharma candidates

Japanese biopharma firm PeptiDream (TYO: 4587) says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium for the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T.

PeptiDream noted that the two agents 177Lu-PSMA-I&T and 64Cu-PSMA-I&T target prostate specific membrane antigen (PSMA) expressed on prostate cancer cells, and are being investigated for prostate cancer for treatment and diagnostics – both targeting tumors with high levels of PSMA expression, and thus potentially forming a theranostic (therapeutic and diagnostic) pair.

Curium and PDRadiopharma will jointly collaborate on clinical development activities of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T in Japan, with PDRadiopharma leading regulatory filing, manufacturing, commercialization, and distribution activities in Japan. Curium will continue to lead global development of the two agents and support PDRadiopharma through technology transfer to support the set-up of manufacturing lines in Japan – including a high throughput Copper 64 manufacturing line based on Curium’s proprietary technology. No financial terms of the collaboration have been disclosed.